Sponsored

Australia’s biotechnology sector has welcomed a new entrant with the launch of Evinco Therapeutics, a Melbourne-based company developing advanced immune therapies aimed at transforming the treatment of Alzheimer’s disease and other neuroinflammatory conditions.

LTR Pharma (ASX:LTP) has secured ethics approval for the next stage of clinical development of its fast-acting erectile dysfunction therapy, paving the way for recruitment to begin early next year and marking another step in the company’s expansion into global markets.

A team of Melbourne researchers has uncovered how subtle electrical signals can direct stem cell behaviour, an advance that could reshape the future of tissue engineering, regenerative medicine, and the development of lab-grown organs.

Island Pharmaceuticals (ASX:ILA) has strengthened its financial position, announcing that directors and substantial shareholders have exercised more than 14.4 million options, delivering just over $1 million in new capital to support the company’s antiviral development programs.

BCAL Diagnostics (ASX:BDX) has taken a significant step toward strengthening clinical confidence in its flagship breast cancer diagnostic, announcing national ethics approval for a large-scale registry that will track outcomes for up to 24,000 Australian women.

Noxopharm (ASX:NOX) has reached a significant milestone in its first-in-human trial of SOF-SKN, announcing that the initial multiple-dose cohort in the HERACLES study has been completed with no safety concerns identified.

Australia’s emerging medtech sector has received a significant boost, with a new report revealing the scale of commercial, clinical and translational progress achieved through MTPConnect’s Clinical Translation and Commercialisation – Medtech (CTCM) Program.

Executive remuneration in Australia’s health care and biotechnology sectors rose modestly in the last financial year, with a 7.2 per cent increase in total CEO pay, according to the 2025 ASX Health Care and Biotechnology Remuneration Report.

CLINUVEL Pharmaceuticals (ASX:CUV) has taken a significant step toward expanding its product portfolio, confirming it is planning to lodge a European regulatory submission for its second pharmaceutical product, NEURACTHEL Instant, by mid-2026.

Imugene (ASX:IMU) has released new clinical data showing an 82 per cent overall response rate in its Phase 1b trial of azer-cel, the company’s allogeneic, off-the-shelf CD19 CAR T therapy for patients with relapsed or refractory diffuse large B-cell lymphoma.

Tetratherix (ASX:TTX) has announced a significant step forward for its US-based joint venture BioOptix, with the ophthalmic biomaterials company signing a development agreement with global eye-care leader Alcon Research.

Melbourne is putting its biomedical and health innovation ecosystem on display as delegates from across Australia and overseas gather in the city for the National Health and Innovation Precincts Summit, the first time the annual event has been hosted in Victoria.